Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma.

被引：0
|
作者：
Kambhampati, Swetha
Saumoy, Monica
Pak, Stacy
Budde, L. Elizabeth
Mei, Matthew Genyeh
Popplewell, Leslie
Wen, Yi-Ping
Forman, Stephen J.
Kwak, Larry W.
Rosen, Steven T.
Herrera, Alex Francisco
Thiruvengadam, Nikhil
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Penn Med Princeton Med Ctr, Plainsboro, NJ USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Univ Texas MD Anderson Canc Ctr Chairman, Houston, TX USA
[6] Loma Linda Univ, Loma Linda, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7568
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL): results of the phase III POLARIX study
    Dietrich, S.
    Tilly, H.
    Morschhauser, F.
    Sehn, L. H.
    Friedberg, J.
    Trneny, M.
    Sharman, J. P.
    Herbaux, C.
    Burke, J. M.
    Matasar, M.
    Rai, S.
    Izutsu, K.
    Mehta-Shah, N.
    Oberic, L.
    Chauchet, A.
    Jurczak, W.
    Song, Y.
    Greil, R.
    Mykhalska, L.
    Burgues, J. M. B.
    Cheung, M. C.
    Pinto, A.
    Shin, H-J
    Hapgood, G.
    Munhoz, E.
    Abrisqueta, P.
    Gau, J-P
    Hirata, J.
    Jiang, Y.
    Yan, M.
    Lee, C.
    Flowers, C.
    Salles, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 193 - 194
  • [32] The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma
    Kawasaki, Natsumi
    Nishito, Yukari
    Yoshimura, Yasushi
    Yoshiura, Shigeki
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) : 245 - 255
  • [33] Polatuzumab vedotin/bendamustine/rituximab (pola-BR) in R/R diffuse large B cell lymphoma with hemophagocytic lymphohistiocytosis
    Chaoyu Wang
    Longrong Ran
    Xi Quan
    Chongling Hu
    Bingling Guo
    Dehong Huang
    Qing Xiao
    Xiaomei Zhang
    Jieping Li
    Zailin Yang
    Yao Liu
    Discover Medicine, 1 (1):
  • [34] New European approval: Polatuzumab vedotin associated to rituximab, cyclophosphamide, doxorubicin and prednisone in previously untreated Diffuse Large B-Cell Lymphoma
    Turot, Melanie
    Requena, Gaspar Aspas
    BULLETIN DU CANCER, 2022, 109 (12) : 1234 - 1235
  • [35] Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
    Olszewski, Adam J.
    Eradat, Herbert
    Avigdor, Abraham
    Horowitz, Netanel A.
    Babu, Sunil
    Levi, Itai
    McKinney, Matthew
    Lee, Seung Tae
    Bergua Burgues, Juan Miguel
    Rodriguez Izquierdo, Antonia
    Bastos-Oreiro, Mariana
    Ganzel, Chezi
    Kim, Tae Min
    Jeon, Youngwoo
    Taszner, Michal
    Narkhede, Mayur
    Kim, Won Seog
    Shin, Ho-Jin
    Lavie, David
    Woszczyk, Dariusz
    Dunshee, Diana
    Kapp, Amy V.
    Zhou, Mingzhu
    Batlevi, Connie Lee
    Ead, Wahib
    Sellam, Gila
    Jurczak, Wojciech
    BLOOD, 2023, 142
  • [36] PHARMACOKINETICS AND DRUG INTERACTION POTENTIAL OF POLATUZUMAB VEDOTIN IN COMBINATION WITH R/G-CHP IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA.
    Shemesh, C. S.
    Agarwal, P.
    Lee, C.
    Dere, R. C.
    Miles, D.
    Li, X.
    Li, C.
    Girish, S.
    Jin, J. Y.
    Lu, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S71 - S71
  • [37] An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma
    Walji, Moneeza
    Assouline, Sarit
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (09) : 933 - 942
  • [38] Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma
    Hajime Yasuda
    Naoko Kaga
    Hikari Taka
    Tomonori Ochiai
    Tomohito Yamana
    Yoshiki Miura
    Midori Ishii
    Makoto Sasaki
    Jun Ando
    Miki Ando
    Cancer Chemotherapy and Pharmacology, 2024, 93 (3) : 265 - 268
  • [39] Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Shingleton, Jennifer R.
    Dave, Sandeep S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 166 - +
  • [40] Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma
    Yasuda, Hajime
    Kaga, Naoko
    Taka, Hikari
    Ochiai, Tomonori
    Yamana, Tomohito
    Miura, Yoshiki
    Ishii, Midori
    Sasaki, Makoto
    Ando, Jun
    Ando, Miki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (03) : 265 - 268
12345